Conclusion
depression, GDM, anxiety
GDM
In summary, we found no difference in maternal mental health outcomes, namely anxiety, depression, and health-related quality of life, measured at 36 weeks’ gestation and 6 months after birth among women with GDM treated with tighter recommended glycaemic treatment targets compared to the previously used less tight glycemic targets in New Zealand. These findings suggest adoption of tighter glycaemic treatment targets in GDM care does not appear to benefit nor harm maternal mental well-being assessed at 36 weeks and 6 months after the birth.